In Mexico, estimates of Chagas disease prevalence and burden vary widely. Updating 23 surveillance data is therefore an important priority to ensure that Chagas disease does not 24 remain a barrier to the development of Mexico's most vulnerable populations.
25

Methodology/Principal Findings
26
The aim of this systematic review was to analyze the literature on epidemiological surveys 27 to estimate Chagas disease prevalence and burden in Mexico, during the period 2006 to 2017.
28
A total of 2,764 articles were screened and 38 were retained for the final analysis.
29
Epidemiological surveys have been performed in most of Mexico, but with variable geographic 30 coverage. Based on studies reporting confirmed cases, i.e. using at least 2 serological tests, the 
Conclusions/Significance
40
Our analysis suggests a disease burden for T. cruzi infection higher than previously 41 recognized, highlighting the urgency of establishing Chagas disease surveillance and control as 42 a key national public health priority in Mexico, to ensure that it does not remain a major barrier 43 to the economic and social development of the country's most vulnerable populations. States principally) [3] . Estimates suggest that 80,000 to 120,000 T. cruzi-infected immigrants 71 live in Europe, and 300,000 live in the United States [4] , and the disease is a growing concern 72 in these regions [5] . The global economic burden of Chagas disease is more than US$ 7.2 73 billion per year, exceeding the costs of other diseases of health impact such as certain cancer 74 (US$6.7 billion for uterine cancer, US$4.7 billion for cervical cancer, and US$5.3 billion for 75 oral cancer) or rotavirus infections (US$ 2 billion) [6, 7] . 
120
For all these articles, titles and abstracts were screened for any indication that the study and not duplicated elsewhere.
128
The ultimate step was to extract the relevant information contained in the selected articles 129 which included 1) publication data (bibliographic information), 2) sampling dates, 3) sampling 130 strategy (archive, random, volunteers, etc…), 4) geographic area covered by the study, 5) 
Results
142
A total of 2,764 articles were screened and 38 were retained for the final analysis (see Figure   143 1). All the articles included in this study corresponded to serological surveys in different We first considered the studies in random populations and in pregnant women (which can 160 be considered as highly representative of the general population as well [55] 
Strengths and limitations
297
A major strength of our analysis was to consider the reliability of serological testing 298 performed, and to ensure it followed WHO recommendation for confirmation of cases using at 299 least a second test. Hence, our estimates of seroprevalence are robust and conservative. On the 300 other hand, there are some limitations. First, some heterogeneity among study designs and 301 particularly sampling strategies and recruitment of subjects may have generated some bias. 
